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A B S T R A C T
Cell-free therapies based on extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs) are
considered as a promising tool for stimulating regeneration and immunomodulation. The need to
develop a practical approach for large-scale production of vesicles with homogenous content led to the
implementation of cytochalasin B-induced to induce microvesicles (CIMVs) biogenesis. CIMVs mimic
natural EVs in size and composition of the surrounding cytoplasmic membrane. Previously we observed
that MSC derived CIMVs demonstrate the same therapeutic angiogenic and immunomodulatory activity
as the parental MSCs, making them a potentially scalable cell-free therapeutic option. However, little is
known about their storage stability and delivery potential. We determined that different storage
conditions alter the protein concentration within the solution used to store CIMVs over time, this
concided with a decrease in the amount of CIMVs due to gradual degradation. We established that
freezing and storage CIMVs in saline at -20 C reduces degredation and prolongs their shelf life.
Additionally, we found that freeze-thawing preserved the CIMVs morphology better than freeze drying
and subsequent rehydration which resulted in aggregation of CIMVs. Collectively our data demonstrates
for the first time, that the most optimal method of CIMVs storage is freezing at -20 C, to preserve the
CIMVs in the maximum quantity and quality with retention of effective delivery. These findings will
benefit the formation of standardized protocols for the use of CIMVs for both basic research and clinical
application.
© 2021 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Extracellular vesicles (EVs) are spherical membrane-protected
vesicles ranging in size from 50 to 2000 nm, released by almost all
human cells and capable of delivering signals to neighboring and
distant cells within an organism [1]. EVs can act as paracrine
effectors, controlling a variety of biological processes by transfer-
ring biologically active molecules (e.g. nucleic acids, proteins and
lipids) to recipient cells [2], changing their phenotype, modulating
the microenvironment [3] and/or triggering receptor-mediated
cell signaling [4–6].
Stem cell (SC) derived EVs carry transcription factors [7–11], cell
surface receptors [12–14] and a molecular content of growth
factors, cytokines and chemokines that reflect the parental cells.
Numerous studies have shown that EVs recapitulate the biological
activity of SCs by stimulating cell proliferation, increasing viability,
inducing chemotaxis [15,16], coordinating recovery processes after
tissue damage by transferring microRNAs [17] and promoting
angiogenesis [18–20], as well as demonstrating immunosuppres-
sion activity [21]. It is hypothesized that EVs can act as a functional
extension of SCs, and the EVs regenerative potential of stem cell
EVs has been used to treat heart, nerve, kidney and liver tissue
damage [22–29].
Cytochalasin B induced membrane vesicles (CIMVs) were
developed as a therapeutic tool in order to allow large-scale
production of vesicles that imitate natural EVs in size and
composition of the surrounding cytoplasmic membrane. CIMVs
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anoparticles in vivo [31], and to stimulate angiogenesis [20].
urthermore, their use for drug delivery has also been postulated,
eng et al. proposed loading of antitumor drugs into CIMVs to
educe unwanted toxicity effects [32].
In our previous work, we isolated CIMVs from neuroblastoma
H-SY5Y cells, prostate PC3 cells [33] and human MSCs [20] and
howed that the size of CIMVs ranges from 100 to 2600 nm, with
he majority (89.36 %) ranging from 100 to 1200 nm [20] and that
he greatest impact on CIMV entry into target cells is the
eterophilic interaction of CIMV membrane receptors with the
urface proteins of target cells [33]. We also demonstrated that
IMVs produced by SH-SY5Y cells contain biologically active
olecules derived from the parental cells and can stimulate the
ormation of capillary-like structures in vitro and angiogenesis in
ivo. More recently we have shown that human CIMVs-MSCs retain
he molecular content, immunophenotype, and angiogenic activity
f parental MSCs [20].
These studies demonstrate that CIMVs are a promising tool for
linical application, particularly within the fields of regenerative
edicine and antitumor therapy. However, little is known about
heir storage stability and delivery potential. In this study we
etermine the effect of storage conditions including freeze-
hawing and freeze-drying on the integrity and delivery effective-
ess of CIMVs derived from human MSCs.
. Materials and methods
.1. MSCs isolation
Human sample collection was approved by the local Ethical
ommittee of Kazan (Volga region) Federal University based on
rticle 20 of the Federal Legislation on "Health Protection of
itizens of the Russian Federation" 323-FL, 21.11.2011. Signed
nformed consent was obtained from each donor. To obtain cell
uspension the adipose tissue was cut into small pieces and treated
ith 0.2 % collagenase II (Dia-M, Russia) in a shaker-incubator at 37
C, 120 rpm for one hour. Cell suspension was pelleted (400 g for 5
in), washed once in PBS (PanEco, Russia) and re-suspended in
MEM (PanEco, Russia) supplemented with 10 % fetal bovine
erum (Gibco, UK) and 2 mM L-glutamine (PanEco, Russia). MSCs
ere maintained at 37 C, 5% CO2 with culture medium replaced
very three days.
.2. HEK293FT cultivation and treatment with CIMVs
HEK293FT (Human Embryonic Kidney 293 cells) (ATCC
umber: CRL-11268), an immortalized primary human embryonic
idney cell line, was grown in DMEM (Paneco, Russia) supple-
ented with 10 % fetal bovine serum (Gibco, UK) and 2 mM L-
lutamine (Paneco, Russia) at 37 C with 5 % CO2. Cell passaging
as performed using a 0.25 % trypsin-EDTA solution (Life
echnologies, USA).
HEK293FT cells were seeded in 96-well culture plates at 20,000
ells per well. After 24 h HEK293FT were treated with CIMVs (250
g/mL) loaded with CFDA SE (650850-84, eBioscience, USA) and
tored under various conditions to evaluate the delivery effective-
ess of CIMVs.
.3. CFDA SE staining
mM; 65-0850-84, eBioscience, USA) for 15 min and washed with
DMEM supplemented with 10 % FBS, 2 mM L-glutamine. CIMVs
were obtained from CFDA SE stained MSCs.
2.4. CIMVs production and storage
CIMVs were prepared as described previously [20,34]. Briefly,
MSCs were washed twice with PBS, and maintained in DMEM
supplementedwith 10mg/mL of Cytochalasin B (Sigma-Aldrich,USA)
for 30 min (37 C, 5 % CO2). Cell suspension was vortexed vigorously
for 30 s and pelleted(100 g for 10 min). The supernatant wascollected
and subject to two subsequent centrifugation steps (300 g for 20 min
and 2000 g for 25 min). The pellet from last step, containing CIMVs-
MSC, was washed once in PBS (2000 g for 25 min). Isolated CIMVs
were resuspended in saline, then divided into separate tubes and
placed in various storage conditions: 1) at +4 C for up to 112 days; 2)
at 20 C for up to 112 days; 3) at 25 C for up to 28 days; 4) freeze
dried and stored at 20 C for 112 days. CIMVs suspension was added
to human serum and stored at 37 C for up to 7 days.
2.5. Characterization of the CIMVs
2.5.1. Scanning electron microscopy (SEM)
CIMVs were fixed with 10 % formalin for 15 min, then
dehydrated using a graded alcohol series and dried at 37 C. Prior
to imaging, samples were coated with gold/palladium in a Quorum
T150ES sputter coater (Quorum Technologies Ltd, United King-
dom). Slides were analyzed using Merlin field emission scanning
electron microscope (CarlZeiss, Germany).
2.5.2. Protein quantification
PierceTM BCA Protein Assay Kit (ThermoScientific, USA) was used
to measure protein concentration in CIMVs storage solutions. Before
the BCA testingof CIMVsstorage solution, CIMVs were sedimentedat
14000 g for 15 min, then storage solution was transferred into a new
tube and used for the following analysis. Thus, we excluded the
CIMVs from the storage solution avoiding influence on the BCA tests.
Further, Protein Assay Kit Reagent A (a solution containing
bicinchoninic acid, sodium carbonate, sodium tartrate, sodium
bicarbonate in 0.1 N NaOH pH 11.25) and Reagent B (4% CuSO4 
5H2O) were mixed in a ratio of 50:1 to prepare working solution.
Then the storage solution sample (25 ml) and working solution (200
ml) were mixed and incubated at 37 C for 30 min. Absorption was
measured 30 min later at 562 nm using a microplate reader (TECAN,
Switzerland). The protein concentration was determined based on
standard dilutions of bovine serum albumin.
2.5.3. Flow cytometry analysis
Quantity of CIMVs was analyzed using flow cytometry (BD FACS
Aria III. BD Bioscience, USA). A 405 nm laser was used for CIMVs-
MSC detection and compared to a suspension of calibration
particles 0.220.45 - 0.88–1.34 - 3.4 mm in size (PPS-6 K,
Spherotech, USA) prepared in PBS.
2.6. Statistical analysis
Statistical analysis was done using Wilcoxon signed-rank test
(R-Studio) with a significance level of p < 0.05. Illustrations were
built with “ggplot2” package.Cell-permeant dye CFDA SE (65-0850-84, eBioscience, USA) was
sed to stain donor MSCs and analyze the integrity of CIMVs during
torage. MSCs were stained with CFDA SE (65-0850-84, eBio-
cience, USA) according to the manufacturer's recommendation.
riefly, MSCs (1  106 cells/mL) were incubated with CFDA SE (102
3. Results
3.1. Protein concentration in CIMV storage solution
The influence of storage conditions on the integrity of CIMVs
was evaluated by determining the protein concentration in the
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suspension of CIMVs was tested to determine the starting protein
concentration of the storage solution (28.65  12.1 mg/mL). The
same solutions were then tested for the protein concentration at
days 1, 3, 7, 14, 28, 56, 84 and 112 to ascertain any changes. In order
to characterize what the protein concentration of the solution
would be after complete degredation of the CIMVs within the
suspension, we used RIPA-buffer to lyse the vesicles and measured
the protein concentration at 396.94  14.5 mg/mL (represented as
the red line in Fig. 1).
The stability of CIMVs in saline is dependent on temperature
and storage time. After 1 day of storage, the protein concentration
in the solution increased to 99.6  13.6 mg/mL,128.5  23.2 mg/mL,
138.1 18.7 mg/mL,199.2  18.4 mg/mL at +4 C, 20 C, +25 C and
after freeze-drying/rehydration, respectively (Fig.1, Table1). Whils
the increase in protein concentration was variable across the time
course in all samples. The trends exhibited demonstrate that
freeze-drying increased the protein content of the storage solution
the most, closely followed by storage of the CIMVs in saline at +25 
C up to day 28. The study of the stability of CIMVs in physiological
saline at +25 C was terminated after 28 days, since during storage
we observed a substantial decrease in the number of whole CIMVs.
The protein concentration at the measuring point of 28 days at +25
C was 225.2  19.1 mg/mL, which is more than half of the
destroyed CIMVs.
Storage of EVs in saline at +4 C and -20 C produced the lowest
increases in protein content within the storage solutions across the
course of the study, indicating the best preservation of intact
CIMVS. After 112 days of storage, the protein concentration in the
solution was 119.7  45.2 mg/mL, 87  14.7 mg/mL,176.3  16.8 mg/
mL at +4 C, -20 C andfreeze drying/rehydration, respectively.
3.2. Influence of storage conditions on amount of CIMVs
The effect of storage conditions and duration on the amount of
CIMVs was evaluated using flow cytometry. The results are shown
in Fig. 2 and listed in Table 2. The concentration of freshly prepared
CIMVs within each storage solution was considered as the control
corresponding to the maximum number of intact CIMVs (665.9 
158(x103)) (Fig. 2). Readings were then taken on days 1, 3, 7, 14, 28,
42, 56, 84, 98 and 112 to ascertain any changes.
After 1 day of storage, the amount of CIMVs decreased in all
conditions to 427.1  19.1(x103), 513.9  15.7(x103), 153.3  23.5
(x103), 253.2  17(x103), 502.4  36.3(x103) at +4 C, -20 C, +25 C,
freeze drying/rehydration and in serum at +37 C, respectively. The
rapid decline in the concentration of CIMVs continued for samples
stored in serum at +37 C, decreasing to 218.2  8(x103) on day 7.
Due to the continuous and rapid decrese in CIMV number, no
further measurements of this condition were made following day
7. A similar, but less extreme, continual decrease in CIMV number
was also seen when storing the vesicles in saline at +25 C. For the
same reason, the investigation under +25 C of storage in saline
was stopped after 28 days when the concentration of CIMVs
reached 317.1  11.5(x103).
Fig. 1. Influence of storage conditions over time on the concentration of protein in CIMV storage solution. The data represent mean  SD of three biological replicates.
Table 1
Protein concentration in CIMVs storage solution.
Storage, C
Days +4 C, (mg/mL) 20 C, (mg/mL) +25 C, (mg/mL) Freeze drying/rehydration, (mg/mL)
0* 28.7  12.1
1 99.6  13.6 128.5  23.2 138.1  18.7 199.2  18.4
3 58.4  24.4 84  9.4 122.2  18.2 142.9  31.4
7 no data 101.9  11.7 163.7  18.6 217.3  29.9
14 103.4  17.5 95.3  24.7 185  40.9 208.9  15.4
28 172.3  19.7 126.5  23.2 225.2  19.1 187.5  40
56 170.8  28.9 113.3  21 – 209.6  27
84 139.7  20.3 133.5  9 – 206.4  71.8
112 119.7  45.2 87  14.7 – 176.3  16.8






















S.K. Kletukhina, O.A. Neustroeva, S.V. Kurbangaleeva et al. Biotechnology Reports 30 (2021) e00616Between days 7 and 70, the tend in CIMV concentration remains
table for storage conditions using saline at +4 C and 20 C
ndfor CIMVs freeze-dried before storage at -20 C. However, after
ay 70, we see a reducing in the number of CIMVs within the
reeze-dried storage condition. At the 112nd day of the investiga-
ion, the amount of CIMVs was 393.9  73.4(x103), 529.5  35.6
x103), 326.6  50.1(x103) at +4 C, 20 C andfreeze drying/
ehydration, respectively. These data further confirm our findings
hat storage of CIMVs in saline at +4 C or -20 C generates the best
onditions for preservation of intact CIMVs.
.3. CIMVs morphology after storage
To further assess the stability of MSCs-derived CIMVs, we
nvestigated the effect of the various storage conditions on the
orphology and integrity of CIMVs after 14 days using SEM. We
maybe adventagous in maintaining the original state of CIMVs
when freshly isolated.
3.4. Delivery effectiveness of CIMVs after storage
CIMVs loaded with CFDA SE were stored under the various
conditions for either 3, 14, 38 or 112 days. The CIMVs were
subsequently thawed/rehydrated and added to recipient cells
(HEK293FT) to evaluate the ability of the CIMVS to deliver CFDA
to the recipient cells. The amount of CFDA-positive recipient cells
(CFDA + cells) was determined 24 h after the addition of the CIMVs by
flow cytometry. As a positive control, freshly prepared CFDA loaded
CIMVs (250 mg/mL) were added to recipient HEK293FTcells for 24 h,
leading to to 98  0.14 % of recipient cells becoming CFDA + positive.
CIMVs destroyed by ultrasound were used as a negative control.
We had previsoly seen that storage of CIMVs in human serum at
Fig. 2. Influence of storage conditions and duration on the quantity of CIMVs in each storage solution. The data represent mean  SD of three biological replicates.
able 2










Serum at +37 C,
(x103)
0* 665.9  158
1 427.1  19.1 513.9  15.7 344.6  52.8 253.2  17 502.4  36.3
3 447.6  146.1 514.7  73 386.6  50.9 260.5  18.2 368.5  18.8
7 330.3  20.3 369.3  17.5 351.3  4.1 442.6  27.2 218.2  8
14 387.4  101.6 307.3  37.7 no data 359.8  41.7 –
28 302.6  37.5 409.5  71.3 317.1  11.5 311.1  45.9 –
42 380.5  62.8 404.7  5.7 – 339.5  78 –
56 336.5  37.9 406  55.9 – 452.6  32.8 –
70 376.1  6.1 359.5  24.4 – 340.1  17.9 –
84 454.6  22.9 419  33.6 – 298  20.1 –
98 345.1  49.1 435.6  46.5 – 219  53.4 –
112 393.9  73.4 529.5  35.6 – 326.6  50.1 –
* Control sample – amount of CIMVs in storage solution immediately after the CIMVs isolation “-” not evaluated.ound that CIMVs immediately after isolation represented spheri-
al structures with a smooth surface (Fig. 3A). The same smooth
pherical appearance was also seen in CIMVs stored in saline at -20
C (Fig. 3C). However, we found that after freeze-drying and
torage in saline at +4 C, CIMVs tended to form more aggregates
Fig. 3B and D). The SEM results indicate storage in saline at -20 C,4
+37 C leads to a decrease in intact CIMVs, again 7 days of storage at
+37 C in serum led to a decrease in the ablity of the stored CIMVs
to deliver CFDA. The percentage of recipient cells with green
fluorescence (CFDA + cells) decreased from 94.5  2.4 % to 79.1 
3.8 % (Fig. 4, black line). No further time points were tested in-line
with the termination points of other assays for this condition.
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C resulted in the percentage of CFDA + recipient cells to decrese to
97.3  0.7 % when treated with CIMVs stored for 3 days, to 88.3 
1.8 % (CIMVs stored for 7 days), 81, 8  1.1 % (CIMVs store for 14
days) and 63.9  0.8 % (CIMVs stored for 28 days) (Fig. 4, green
line). Similarly, to storage in serum, storage of CIMVs in salines at
+25 C had previously seen to caue a decrease in intact CIMVs, this
assay indicates the same occurance with the continuous and
substanitial reduction in CFDA + recipient cells. Therefore, no
further data points were measured in-line with the termination
points of other assays for this condition.
When applying CIMVs, which were stored in saline at 4 C, the
percentage of CFDA + recipient cells decreased from 97.7  0.17 %
(CIMVs stored for 3 days) to 93.88  2.18 % (CIMVs stored for 14
days), 90.9  1.19 % (CIMVs stored for 28 days), 60.2  2.4 % (CIMVs
stored for 112 days) (Fig. 4, red line).
The effects of storing CIMVs at -20 C, resulted in the most
effective transfer of CFDA to recipient cells. Storage of CIMVs in
saline at -20 C for 112 days followed by a single thaw led to a
decrease in the percentage of CFDA + recipient cells to 71.16  3.12
% (Fig. 4, blue line). Freeze drying and storage of CMVs for 112 days
followed by rehydration led to a decrease in the percentage of
CFDA + recipient cells to 86.46  4.04 % (Fig. 4, dark green line).
4. Discussion
Here, for the first time, we analyze the storage stability and
delivery potential of cytochalasin B induced membrane vesicles.
Fig. 3. Microphotographs of membrane vesicles subjected to different storage conditions. Scanning electron microscopy. A - control (membrane vesicles immediately after
isolation); B - membrane vesicles after 14 days of storage in saline at + 4 C; C - membrane vesicles after 14 days of storage in saline at -20 C; D - membrane vesicles after 14
days of storage, subjected to freeze-drying / rehydration.Fig. 4. Delivery effectiveness of CIMVs. CFDA loaded CIMVs were added to recipient cells after 1) freeze-drying/rehydration (dark green line); 2) storage in saline at -20 C
(blue line); 3) storage in saline at +4 C (red line); storage in saline at +25 C (green line); incubation of CIMVs in a serum at +37 C (black line). The percent of CFDA + cells after
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IMV-containing storage solutions increases over time due to the
radual degradation of CIMVs. The most profound changes in
rotein concentration were observed when CIMVs were stored in
aline at +25 C, with protein concentrations increasing 7.8 times
fter 28 days of storage. Similarly, storage of CIMVs in saline at +4 
 also led to increased protein concentration in the CIMV storage
olution to 4.1 times. Freeze-drying/rehydration also effected
rotein concentration in the CIMV storage solution, increasing
rotein concentration 6.1-fold over the course of the storage
eriod. Our data revealed that the most effective preservation
ethod of CIMVs is storage in saline at -20 C, since after 112 days
f storage the protein concentration in the CIMVs storage solution
ncreased only 3-fold.
To further determine how storage effects CIMV number, we
nalyzed CIMVs following storage by flow cytometry. In addition to
he storage conditions previously studied, we also evaluated the
tability of CIMVs in human serum at 37 C imitating the internal
nvironment of human body. We found a significant decrease in
he amount of CIMVs in human serum during the observation
eriod. After 7 days of storage only 30 % of CIMVs remained intact
CIMVs decreased from 665.9  158(103) to 218.2  8(103)). Storage
t +25 C in saline for 28 days led to preservation of 47.7 % of CIMVs,
ecreasing the temperature to +4 C prolonged the shelf life of
IMVs to 112 days with preservation of 59 % of CIMVs. Freeze
rying led to 49 % of CIMVs remaining intact. Whilst freezing
IMVs suspended in saline at - 20 C preserved 79.5 % CIMVs. In
ddition, we found that freezing at - 20 C preserved the CIMVs
orphology, whereas freeze-drying and storage at +4 C led to
ggregating of CIMVs.
Our data corroborate results obtained by LÅrincz et al. who
emonstrated that storage of EVs derived from neutrophilic
ranulocytes at +4 C for 1 day resulted in a significant decrease
n EV concentration. The authors also observed that storage at -20 
 did not affect the number of EVs for up to 28 days of storage, but
aused a change in the size of the EVs and an almost complete loss
f antibacterial function after 28 days [35].
Park and co-authors observed that the stability of EV surface
roteins was significantly affected by storage at 37 C for 16 days,
nd maintained during storage at +4 C, 20 C and70 C for 25
ays [36]. Previously we have shown that delivery effectiveness of
IMVs greatly depends on heterophilic interaction of CIMV
embrane receptors with the surface proteins of target cells
33]. Here we observed that the effectiveness of CIMVs to deliver
argo after the storage in saline under different conditions
ncreased in the following order: storage at +25 C, +4 C, freezing
t 20 C andfreeze drying/rehydration. In this way, our findings
re concordant with those of Park et al., and taken together
ndicate the delivery effectiveness of CIMVs is connected with
reservation of surface proteins during storage at decreased
emperature. The storage of samples to lower temperatures (e.g.
7080 C) as Park et al., used, may replicate the findings we
bserved at - 20 C. However, use of such conditions is not
enerally conducive to wide-spread clinical use and as such were
ot included in our study. Despite of CIMVs demonstrated high
elivery efficiency after freeze drying/rehydration, their stability
nd integrity were lower compared to storing at +4 C and 20 C
ccording to protein quantification and flow cytometry analysis
Figs. 1 and 2). We suppose that the observed high delivery
fficiency of CIMVs after freeze drying / rehydration might be due
potential of CIMVs. We found that optimal method of CIMVs
storage is freezing at 20 C in saline. For the first time we
demonstrated that this method allows the preservation of CIMVs
in high quantities which retain physically features and delivery
effectiveness. Freeze drying prior to storage at 20 C also
produced good results, but issues with aggregation of CIMVs first
need to be overcome. The solution to which may lie in the
evaluation of the use of cryoprotectants.
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